- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | PROKIDNEY CORP. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 17.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.03. | ProKidney GAAP EPS of -$0.62 | 2 | Seeking Alpha | ||
| 17.03. | PROKIDNEY CORP. Full Year Loss Increases | - | RTTNews | ||
| 17.03. | ProKidney Reports Full Year 2024 Financial Results and Business Highlights | 124 | GlobeNewswire (Europe) | Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing... ► Artikel lesen | |
| 21.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.11.24 | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | ProKidney GAAP EPS of -$0.14 | 2 | Seeking Alpha | ||
| 12.11.24 | ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting | 135 | GlobeNewswire (Europe) | FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed... ► Artikel lesen | |
| 09.08.24 | ProKidney Reports Business Updates and Second Quarter 2024 Financial Results | 269 | GlobeNewswire (Europe) | Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT... ► Artikel lesen | |
| 10.06.24 | ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates | 183 | GlobeNewswire (Europe) | Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and... ► Artikel lesen | |
| 10.05.24 | ProKidney Reports Business Updates and First Quarter 2024 Financial Results | 338 | GlobeNewswire (Europe) | Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVOSIM LABS | 1,930 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,680 | -0,59 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| GENMAB | 179,45 | -0,44 % | H.C. Wainwright maintains Buy on Genmab shares, $37 price target | ||
| LEAP THERAPEUTICS | 0,162 | -34,68 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ --... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,073 | -100,00 % | Enveric Biosciences, Inc.: Enveric Biosciences Participating in BIO-Europe Spring | Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 0,419 | +2,80 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer | WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases... ► Artikel lesen | |
| REPARE THERAPEUTICS | 1,330 | 0,00 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| BIOATLA | 0,440 | 0,00 % | BioAtla, Inc.: BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting | ||
| RELMADA THERAPEUTICS | 0,590 | -9,23 % | Relmada Therapeutics Aktie: Auf einer Gratwanderung | Das Biotechnologie-Unternehmen Relmada Therapeutics steht vor einem bedeutenden Wendepunkt in seiner Unternehmensgeschichte. Nach einer umfassenden Bewertung durch das Datenüberwachungskomitee hat sich... ► Artikel lesen | |
| THERANEXUS | 0,372 | -1,85 % | THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT | Lyon, France - 30 January 2025, 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as... ► Artikel lesen | |
| BOUNDLESS BIO | 1,510 | 0,00 % | Boundless Bio, Inc.: Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 0,394 | 0,00 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
| PEPGEN | 1,680 | 0,00 % | PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment... ► Artikel lesen | |
| TEMPUS AI | 53,50 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,170 | 0,00 % | Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock |
Das Unternehmen PROKIDNEY CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.
